In Vitro Activities of the β-Lactamase Inhibitors Clavulanic Acid, Sulbactam, and Tazobactam Alone or in Combination with β-Lactams against Epidemiologically Characterized Multidrug-Resistant Acinetobacter baumannii Strains
Open Access
- 1 May 2004
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (5) , 1586-1592
- https://doi.org/10.1128/aac.48.5.1586-1592.2004
Abstract
Acinetobacter baumannii is an important nosocomial pathogen usually in the context of serious underlying disease. Multidrug resistance in these organisms is frequent. The β-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam have intrinsic activity against Acinetobacter strains. To evaluate their potential therapeutic usefulness, we determined the in vitro activity of ampicillin, sulbactam, ampicillin-sulbactam, cefoperazone, cefoperazone-sulbactam, piperacillin, piperacillin-sulbactam, tazobactam, piperacillin-tazobactam, amoxicillin, clavulanic acid, amoxicillin-clavulanic acid, ticarcillin, and ticarcillin-clavulanic acid against multidrug-resistant A. baumannii. All isolates were epidemiologically characterized by RAPD [random(ly) amplified polymorphic DNA] analysis and/or pulsed-field gel electrophoresis and represented different strain types, including sporadic strains, as well as outbreak-related strains. The MICs were determined by agar dilution on Mueller-Hinton agar (using fixed concentrations, as well as fixed ratios for β-lactamase inhibitors) and the E-test. The majority of E-test results were within two dilutions of those recorded by agar dilution, with the exception of piperacillin-tazobactam. Sulbactam was superior to clavulanic acid and tazobactam and may represent an alternative treatment option for infections due to multiresistant A. baumannii strains. β-Lactamase inhibitors have intrinsic activity but do not enhance activity of β-lactams against A. baumannii. Testing with the inhibitor added at a fixed concentration as recommended for piperacillin-tazobactam and ticarcillin-clavulanic acid by the National Committee for Clinical Laboratory Standards may falsely suggest high activity or gives uninterpretable results due to trailing. If combinations are used for testing, fixed ratios may give more useful results.Keywords
This publication has 37 references indexed in Scilit:
- Comparison of Ampicillin‐Sulbactam and Imipenem‐Cilastatin for the Treatment ofAcinetobacterVentilator‐Associated PneumoniaClinical Infectious Diseases, 2002
- Characterization of OXA-25, OXA-26, and OXA-27, Molecular Class D β-Lactamases Associated with Carbapenem Resistance in Clinical Isolates of Acinetobacter baumanniiAntimicrobial Agents and Chemotherapy, 2001
- Nosocomial Bloodstream Infections Caused by Acinetobacter Species in United States Hospitals: Clinical Features, Molecular Epidemiology, and Antimicrobial SusceptibilityClinical Infectious Diseases, 2000
- Carbapenem resistance mediated by Beta-lactamases in clinical isolates ofAcinetobacter baumannii in SpainEuropean Journal of Clinical Microbiology & Infectious Diseases, 1998
- Imipenem resistance among Acinetobacter baumannii: association with reduced expression of a 33–36 kDa outer membrane proteinJournal of Antimicrobial Chemotherapy, 1996
- Susceptibility testing with clavulanic acid: fixed concentration versus fixed ratioAntimicrobial Agents and Chemotherapy, 1995
- Nosocomial Bacteremia due to Acinetobacter baumannii: Clinical Features, Epidemiology, and Predictors of MortalityMedicine, 1995
- Interaction of sulbactam, clavulanic acid and tazobactam with penicillin-binding proteins of imipenem-resistant and -susceptible acinetobacter baumanniiFEMS Microbiology Letters, 1995
- Interaction of sulbactam, clavulanic acid and tazobactam with penicillin-binding proteins of imipenem-resistant and -susceptibleacinetobacter baumanniiFEMS Microbiology Letters, 1995
- Amantadine prophylaxis for health care workers: unanswered questionsJournal of Antimicrobial Chemotherapy, 1991